These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 19670296)

  • 81. Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of norfloxacin in rats.
    Chenel M; Barbot A; Dupuis A; Mimoz O; Paquereau J; Bouquet S; Couet W
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1952-7. PubMed ID: 12760873
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of imipenem in healthy rats.
    Dupuis A; Couet W; Paquereau J; Debarre S; Portron A; Jamois C; Bouquet S
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1682-7. PubMed ID: 11353611
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Gemifloxacin for community-acquired pneumonia.
    Lode HM; Schmidt-Ionas M; Stahlmann R
    Expert Opin Investig Drugs; 2008 May; 17(5):779-86. PubMed ID: 18447602
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Gemifloxacin use in the treatment of acute bacterial exacerbation of chronic bronchitis.
    Jivcu C; Gotfried M
    Int J Chron Obstruct Pulmon Dis; 2009; 4():291-300. PubMed ID: 19684863
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Role of gemifloxacin in the management of community-acquired lower respiratory tract infections.
    Blondeau JM; Tillotson G
    Int J Antimicrob Agents; 2008 Apr; 31(4):299-306. PubMed ID: 18276120
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections.
    Yoo BK; Triller DM; Yong CS; Lodise TP
    Ann Pharmacother; 2004; 38(7-8):1226-35. PubMed ID: 15187209
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Fluoroquinolones in the management of community-acquired pneumonia in primary care.
    Wispelwey B; Schafer KR
    Expert Rev Anti Infect Ther; 2010 Nov; 8(11):1259-71. PubMed ID: 21073291
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Optimal antibiotic dosing. The pharmacokinetic-pharmacodynamic interface.
    Reed MD
    Postgrad Med; 2000 Dec; 108(7 Suppl Contemporaty):17-24. PubMed ID: 19667545
    [TBL] [Abstract][Full Text] [Related]  

  • 89. A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context.
    Ball P; Mandell L; Patou G; Dankner W; Tillotson G
    Int J Antimicrob Agents; 2004 May; 23(5):421-9. PubMed ID: 15120718
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Gemifloxacin.
    Lowe MN; Lamb HM
    Drugs; 2000 May; 59(5):1137-47; discussion 1148. PubMed ID: 10852645
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones.
    Segreti J; Jones RN; Bertino JS
    J Ocul Pharmacol Ther; 2012 Feb; 28(1):3-11. PubMed ID: 21999341
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Convulsant activity and pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of gemifloxacin in rats.
    Roy B; Bose A; Bhaumik U; Das A; Chatterjee N; Ghosh A; Darbar S; Sarkar AK; Sengupta P; Pal TK
    J Pharm Sci; 2010 Mar; 99(3):1535-47. PubMed ID: 19670296
    [TBL] [Abstract][Full Text] [Related]  

  • 93.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 94.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 5.